We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+2.49%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$280M
AUM Growth
-$281M
Cap. Flow
-$284M
Cap. Flow %
-101.42%
Top 10 Hldgs %
74.06%
Holding
63
New
4
Increased
2
Reduced
14
Closed
32

Top Buys

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$1.74M
2
ECYT
Endocyte, Inc. Common Stock
ECYT
+$1.58M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$377K
4
AMRN
Amarin Corp
AMRN
+$268K
5
CHRS icon
Coherus Oncology
CHRS
+$151K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$63.8M
2
ARGX icon
argenx
ARGX
+$30.9M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$25.6M
4
VCYT icon
Veracyte
VCYT
+$17.3M
5
ASND icon
Ascendis Pharma A/S
ASND
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 72.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
26
Amarin Corp
AMRN
$297M
$1.16M 0.41%
+3,550
New +$268K
CHRS icon
27
CALL
Coherus Oncology
CHRS
$222M
$825K 0.29%
50,000
– –
AMAG
28
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$800K 0.29%
40,000
-10,000
-20% -$228K
ALIM
29
DELISTED
Alimera Sciences
ALIM
$262K 0.09%
17,833
-47,122
-73% -$717K
ONCT
30
PUT
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$157K 0.06%
+714
New +$1.71M
OTLK icon
31
Outlook Therapeutics
OTLK
$171M
$29K 0.01%
182
– –
APLS
32
DELISTED
Apellis Pharmaceuticals
APLS
– –
-168,000
Closed -$3.7M
DB icon
33
PUT
Deutsche Bank
DB
$69.8B
– –
-150,000
Closed -$1.59M
EDIT icon
34
CALL
Editas Medicine
EDIT
$407M
– –
-50,000
Closed -$1.79M
EEM icon
35
PUT
iShares MSCI Emerging Markets ETF
EEM
$28.9B
– –
-150,000
Closed -$6.5M
ESPR
36
PUT
DELISTED
Esperion Therapeutics
ESPR
– –
-25,000
Closed -$980K
FENC icon
37
Fennec Pharmaceuticals
FENC
$333M
– –
-250,000
Closed -$2.61M
GYRE icon
38
Gyre Therapeutics
GYRE
$681M
– –
-110,667
Closed -$9.69M
INDP icon
39
Indaptus Therapeutics
INDP
$175M
– –
-1,323
Closed -$13M
IOVA icon
40
CALL
Iovance Biotherapeutics
IOVA
$1.93B
– –
-190,000
Closed -$2.43M
KZR
41
DELISTED
Kezar Life Sciences
KZR
– –
-10,000
Closed -$1.73M
LRMR icon
42
Larimar Therapeutics
LRMR
$413M
– –
-20,833
Closed -$2.56M
LITS
43
Lite Strategy Inc
LITS
$33.4M
– –
-44,004
Closed -$3.47M
MNKD icon
44
PUT
MannKind Corp
MNKD
$1.17B
– –
-107,500
Closed -$204K
OSUR icon
45
PUT
OraSure Technologies
OSUR
$286M
– –
-50,000
Closed -$824K
RMTI icon
46
PUT
Rockwell Medical
RMTI
$28.5M
– –
-227
Closed -$123K
SRPT icon
47
Sarepta Therapeutics
SRPT
$1.68B
– –
-60,000
Closed -$7.93M
STAA icon
48
PUT
STAAR Surgical
STAA
$1.21B
– –
-25,000
Closed -$775K
VCEL icon
49
Vericel Corp
VCEL
$2.36B
– –
-190,055
Closed -$1.84M
VKTX icon
50
Viking Therapeutics
VKTX
$3.8B
– –
-750,000
Closed -$7.12M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2018 Portfolio in Review

As of Q3 2018, Acuta Capital Partners held 63 positions worth $280M, down 50% from $562M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Acuta Capital Partners withdrew a net $284M in Q3 2018, closing 32 positions and reducing 14 holdings. Its most notable exit was Indaptus Therapeutics, an estimated $13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 68% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in KalVista Pharmaceuticals worth $2.85M.

  • Acuta Capital Partners's largest Q3 2018 buy was KalVista Pharmaceuticals: 128,844 shares worth $2.85M.
  • Acuta Capital Partners added most to Xenon Pharmaceuticals in Q3 2018, an estimated $377K increase.
  • Acuta Capital Partners's biggest Q3 2018 reduction was Immunomedics Inc, cutting an estimated $63.8M.
  • Acuta Capital Partners fully exited Indaptus Therapeutics in Q3 2018, selling an estimated $13M.
  • Acuta Capital Partners's ten largest holdings make up 74% of its $280M portfolio in Q3 2018.
  • Acuta Capital Partners opened 4 new positions and closed 32 in Q3 2018.
  • Acuta Capital Partners's portfolio value fell 50% quarter-over-quarter to $280M.

Based on Acuta Capital Partners's 13F filing for Q3 2018, filed 7 Nov 2018.